½ÃÀ庸°í¼­
»óǰÄÚµå
1726389

¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® - Á¢¼Ó ¹æ¹ýº°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

U.S. Continuous Positive Airway Pressure Devices Market Size, Share & Trends Analysis Report By Connectivity (Connected, Non-connected), By End-use (Home Care Settings, Hospitals & Clinics), And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 80 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀåÀº 2025-2030³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 4.44%¸¦ ±â·ÏÇÒ Àü¸ÁÀ̸ç, 2030³â¿¡´Â 8¾ï 2,085¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ ½ÃÀåÀº ¼ö¸é¹«È£Èí ÁõÈıº°ú È£Èí±â Áúȯ À¯º´·ü Áõ°¡, Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ±â¼úÀÇ Áøº¸, ¼ö¸é ¹«È£Èí ÁõÈıº¿¡ ´ëÇÑ ÀÎ½Ä ¹× Áø´Ü Áõ°¡, Áö¿øÀûÀÎ »óȯ Á¤Ã¥ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù.

±â¼ú Áøº¸´Â ¹Ì±¹ÀÇ CPAP ½ÃÀåÀÇ ¶Ç ´Ù¸¥ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. ²÷ÀÓ¾ø´Â ±â¼ú Çõ½Å¿¡ ÀÇÇØ, º¸´Ù »ç¿ëÇϱ⠽±°í, º¸´Ù Á¶¿ëÇϰí ÄÄÆÑÆ®ÇÑ ±â±â°¡ °³¹ßµÇ¾î ȯÀÚÀÇ ÄèÀû¼º°ú ÄÄÇöóÀ̾𽺰¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ¿¬°á±â´É µî Çõ½ÅÀûÀÎ ±â¼úÀ» µµÀÔÇÔÀ¸·Î½á ȯÀÚ´Â ÀÚ½ÅÀÇ ¼ö¸é ÆÐÅϰú Ä¡·á °æ°ú¸¦ ÃßÀûÇÒ ¼ö ÀÖ°Ô µÅ ÀÇ·á¿¡ ´ëÇÑ Àû±ØÀûÀÎ °ü¿©°¡ ÃËÁøµË´Ï´Ù.

ÀÇ·á±â°ü ¹× Á¤ºÎ±â°ü¿¡ ÀÇÇÑ °è¸ù Ä·ÆäÀÎ Áõ°¡¿¡ ÀÇÇØ ¼ö¸é½Ã ¹«È£Èí ÁõÈıºÀÇ Áø´ÜÀ̳ª Ä¡·á¸¦ ¿ä±¸ÇÏ´Â »ç¶÷ÀÌ ´Ã°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ º¸Çè ȸ»ç¿¡ ÀÇÇÑ È£ÀÇÀûÀΠȯºÒ Á¤Ã¥¿¡ ÀÇÇØ, CPAP ¿ä¹ýÀº º¸´Ù Æø³ÐÀº Ãþ¿¡ À־ ÀÌ¿ëÇϱ⠽¬¿öÁö°í ÀÖ½À´Ï´Ù. Ä¡·áµÇÁö ¾ÊÀº ¼ö¸é¹«È£ÈíÁõ¿¡ µû¸¥ ÇÕº´Áõ ¿¹¹æÀ̶ó´Â CPAP ¿ä¹ýÀÇ Àå±âÀûÀÎ ÀåÁ¡ÀÌ Àνĵʿ¡ µû¶ó ÀÇ·á Á¦°øÀڵ鵵 ÀÚÁÖ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â¸¦ ±ÇÀåÇϰí ó¹æÇÏ°Ô µÇ¾ú½À´Ï´Ù.

¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð ±â±â ½ÃÀå : ºÐ¼® °³¿ä

  • Á¢¼Ó ¹æ½Äº°·Î´Â Á¢¼Ó½ÄÀÌ 2024³â¿¡ 68.83%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº ½Ç½Ã°£ ¸ð´ÏÅ͸µ ¹× ¸ÂÃãÇü Ä¡·á¸¦ À§ÇÑ ±â¼ú ÅëÇÕ °³¼± µî ¼ö¸é¹«È£ÈíÁõ °ü¸®ÀÇ Áøº¸°¡ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â ÀçÅà ġ·á ºÐ¾ß°¡ 2024³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£¿¡´Â °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ È®´ë´Â Æó¼â¼º ¼ö¸é¹«È£ÈíÁõ(OSA) À¯º´·ü Áõ°¡¿Í CPAP ±â¼úÀÇ Áøº¸·Î ÀÎÇØ ¹ß»ýÇϸç, ȯÀÚ¿¡°Ô Àú·ÅÇϰí ÄèÀûÇÏ¸ç Æí¸®ÇÑ ¼Ö·ç¼ÇÀ¸·Î ÀçÅà ÀÇ·á¿ë CPAP ¿ä¹ýÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • ¹Ì±¹ CPAP ±â±â ½ÃÀåÀÇ À¯·Â ±â¾÷Àº ResMed, Koninklijke Philips NV, Fisher & Paykel Healthcare Limited, Medical Depot, Inc. µîÀÌ ÀÖ½À´Ï´Ù
  • 2024³â 11¿ù, ÇǼŠ& ÆäÀÌÄÌÇコÄɾî´Â ¹Ì±¹¿¡¼­ F&P Nova Micro ÄÚ º£°³ ¸¶½ºÅ©¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀåÀÇ º¯µ¿ ¿äÀÎ, °æÇâ ¹× ¹üÀ§

  • ½ÃÀå ¿¬°ü Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã ¹× ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ ¹× Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • ½ÃÀå ±âȸ ºÐ¼®
    • ½ÃÀå °úÁ¦ ºÐ¼®
  • ¹Ì±¹ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : ºÐ¼® µµ±¸, PESTEL ºÐ¼®
    • Á¤Ä¡ ¹× ¹ý·ü
    • °æÁ¦ ¹× »çȸ
    • ±â¼ú
    • ȯ°æ
  • ¹Ì±¹ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : Porter's Five Forces ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå ¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : Á¢¼Ó ¹æ¹ýº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : Á¢¼Ó ¹æ¹ýº° º¯µ¿ ºÐ¼®
  • ¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : Á¢¼Ó ¹æ¹ýº° ´ë½Ãº¸µå
  • ½ÃÀå µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼® : Á¢¼Ó ¹æ¹ýº°(2024³â, 2030³â)
  • Á¢¼Ó ¹æ¹ýº°
  • Á¢¼Ó½Ä
    • ºí·çÅõ½º Á¢¼Ó CPAP
    • Wi-Fi ¹× ¼¿·ê·¯ Á¢¼Ó CPAP
    • ÇÏÀ̺긮µå Á¢¼Ó
  • ºñÁ¢¼Ó½Ä

Á¦5Àå ¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤ ¹× µ¿Ç⠺м®

  • ¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° º¯µ¿ ºÐ¼®
  • ¹Ì±¹ÀÇ Áö¼Ó±âµµ¾ç¾Ð(CPAP) ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ´ë½Ãº¸µå
  • ½ÃÀå µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼® : ÃÖÁ¾ ¿ëµµº°(2024³â, 2030³â)
  • ÃÖÁ¾ ¿ëµµº°
  • ÀçÅà ġ·á
  • º´¿ø ¹× Ŭ¸®´Ð
  • ±âŸ(°£º´ ½Ã¼³ µî)

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • ÁÖ¿ä ±â¾÷ÀÇ ÁøÀÔ ¹× ÅðÃâ Àü·«°ú °æÀï»ç¿¡ ´ëÇÑ ¿µÇâ
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´× ºÐ¼®
  • ±â¾÷º° Á¡À¯À² ºÐ¼®(%, 2012-2024³â)
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ ¹× »óÀå ±â¾÷
    • ResMed
    • Koninklijke Philips NV
    • Fisher &Paykel Healthcare Limited
    • React Health(3B Medical)
    • Lowenstein Medical
    • BMC Medical
    • Wellell(Apex Medical)
    • Armstrong Medical
    • Breas Medical
    • SEFAM
    • Smiths Group PLC
    • Transcend Inc.(Somnetics International, Inc.)
    • Trudell Medical(Vyaire)
    • Medical Depot, Inc. dba Drive DeVilbiss Healthcare.
    • Invacare Corporation
    • ±âŸ
AJY 25.05.29

U.S. Continuous Positive Airway Pressure Devices Market Growth & Trends:

The U.S. continuous positive airway pressure devices market is anticipated to reach USD 820.85 million by 2030, registering a CAGR of 4.44% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several factors, including the increasing prevalence of sleep apnea and respiratory conditions, advancements in CPAP device technology, increased awareness and diagnosis of sleep apnea, and supportive reimbursement policies.

Technological advancements represent another crucial driver in the U.S. CPAP market. Continuous innovation has led to the development of more user-friendly, quieter, and compact devices, enhancing patient comfort and compliance. Introducing innovative technologies, such as remote monitoring and connectivity features, allows patients to track their sleep patterns and treatment progress, driving an active role in their healthcare.

Increased awareness campaigns by healthcare organizations and government bodies lead to more individuals seeking diagnosis and treatment for sleep apnea. In addition, favorable reimbursement policies by insurance providers make CPAP therapy more accessible to a broader population segment. Recognizing the long-term benefits of CPAP therapy in preventing complications associated with untreated sleep apnea also encourages healthcare providers to recommend and prescribe these devices frequently.

U.S. Continuous Positive Airway Pressure Devices Market Report Highlights:

  • On the basis of connectivity, the connected segment held the largest market share of 68.83% in 2024 and is anticipated to grow at the fastest CAGR for the forecast period. The growth of this segment is driven by advancements in sleep apnea management, including improved technology integration for real-time monitoring and tailored care, which enhances user adherence and treatment effectiveness.
  • On the basis of end use, the home care settings segment held the largest market share in 2024 and is anticipated to grow at the fastest CAGR for the forecast period. The expansion of this segment is driven by the increasing prevalence of obstructive sleep apnea (OSA) and advancements in CPAP technology, which are increasing the adoption of homecare CPAP therapy as an affordable, comfortable, and convenient solution for patients.
  • Some prominent players in the U.S. CPAP devices market include ResMed, Koninklijke Philips N.V., Fisher & Paykel Healthcare Limited, and Medical Depot, Inc. dba Drive DeVilbiss Healthcare.
  • In November 2024, Fisher & Paykel Healthcare introduced the F&P Nova Micro nasal pillow mask in the U.S., marking the company's smallest and lightest CPAP therapy mask so far.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. CPAP Devices Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Connectivity segment outlook
      • 2.1.2.2. End Use segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Rising incidence of obstructive sleep apnea (OSA)
      • 3.3.1.2. Technological advancements
      • 3.3.1.3. Supportive initiatives by government and private organizations for CPAP devices
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Product recalls & failure
      • 3.3.2.2. Complex regulatory framework pertaining to CPAP devices
    • 3.3.3. Market Opportunity Analysis
      • 3.3.3.1. Growing adoption of CPAP devices in home care settings
    • 3.3.4. Market Challenges Analysis
      • 3.3.4.1. Regulatory and reimbursement challenges
  • 3.4. U.S. CPAP Devices Market Analysis Tools: PESTEL
    • 3.4.1. Political & Legal
    • 3.4.2. Economic & Social
    • 3.4.3. Technology
    • 3.4.4. Environment
  • 3.5. U.S. CPAP Market Analysis Tools: Porter's
  • 3.6. COVID 19 Impact Analysis

Chapter 4. U.S. CPAP Devices Market: Connectivity Estimates & Trend Analysis

  • 4.1. U.S. CPAP Devices Market: Connectivity Movement Analysis
  • 4.2. U.S. CPAP Devices Market: Connectivity Segment Dashboard
  • 4.3. Connectivity Movement & Market Share Analysis, 2024 & 2030
  • 4.4. U.S. Connectivity Market Estimates & Forecast, by Connectivity
  • 4.5. Connected
    • 4.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million) (000' Units)
    • 4.5.2. Bluetooth-Connected CPAP
      • 4.5.2.1. Market Estimates & Forecast, 2018 - 2030 (USD Million) (000' Units)
    • 4.5.3. Wi-Fi & Cellular Connected CPAP
      • 4.5.3.1. Market Estimates & Forecast, 2018 - 2030 (USD Million) (000' Units)
    • 4.5.4. Hybrid-Connected
      • 4.5.4.1. Market Estimates & Forecast, 2018 - 2030 (USD Million) (000' Units)
  • 4.6. Non-Connected
    • 4.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million) (000' Units)

Chapter 5. U.S. CPAP Devices Market: End Use Estimates & Trend Analysis

  • 5.1. U.S. CPAP Devices Market: End Use Movement Analysis
  • 5.2. U.S. CPAP Devices Market: End Use Segment Dashboard
  • 5.3. End Use Movement & Market Share Analysis, 2024 & 2030
  • 5.4. U.S. CPAP Devices Market Estimates & Forecast, by End Use
  • 5.5. Home Care Settings
    • 5.5.1. Market Estimates & Forecast, 2018 - 2030 (USD Million) (000' Units)
  • 5.6. Hospitals & Clinics
    • 5.6.1. Market Estimates & Forecast, 2018 - 2030 (USD Million) (000' Units)
  • 5.7. Others (Long-Term Care Facilities, etc.)
    • 5.7.1. Market Estimates & Forecast, 2018 - 2030 (USD Million) (000' Units)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategies of Market Players for Entry and Exit and its Impact on Market Competitors
  • 6.3. Company Market Position Analysis
  • 6.4. Company Share Analysis, from 2012 to 2024 (%)
  • 6.5. Company Profiles/Listing
    • 6.5.1. ResMed
      • 6.5.1.1. Overview
      • 6.5.1.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.1.3. Product benchmarking
      • 6.5.1.4. Strategic initiatives
    • 6.5.2. Koninklijke Philips N.V.
      • 6.5.2.1. Overview
      • 6.5.2.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.2.3. Product benchmarking
      • 6.5.2.4. Strategic initiatives
    • 6.5.3. Fisher & Paykel Healthcare Limited
      • 6.5.3.1. Overview
      • 6.5.3.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.3.3. Product benchmarking
      • 6.5.3.4. Strategic initiatives
    • 6.5.4. React Health (3B Medical)
      • 6.5.4.1. Overview
      • 6.5.4.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.4.3. Product benchmarking
      • 6.5.4.4. Strategic initiatives
    • 6.5.5. Lowenstein Medical
      • 6.5.5.1. Overview
      • 6.5.5.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.5.3. Product benchmarking
      • 6.5.5.4. Strategic initiatives
    • 6.5.6. BMC Medical
      • 6.5.6.1. Overview
      • 6.5.6.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.6.3. Product benchmarking
      • 6.5.6.4. Strategic initiatives
    • 6.5.7. Wellell (Apex Medical)
      • 6.5.7.1. Overview
      • 6.5.7.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.7.3. Product benchmarking
      • 6.5.7.4. Strategic initiatives
    • 6.5.8. Armstrong Medical
      • 6.5.8.1. Overview
      • 6.5.8.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.8.3. Product benchmarking
      • 6.5.8.4. Strategic initiatives
    • 6.5.9. Breas Medical
      • 6.5.9.1. Overview
      • 6.5.9.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.9.3. Product benchmarking
      • 6.5.9.4. Strategic initiatives
    • 6.5.10. SEFAM
      • 6.5.10.1. Overview
      • 6.5.10.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.10.3. Product benchmarking
      • 6.5.10.4. Strategic initiatives
    • 6.5.11. Smiths Group PLC
      • 6.5.11.1. Overview
      • 6.5.11.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.11.3. Product benchmarking
      • 6.5.11.4. Strategic initiatives
    • 6.5.12. Transcend Inc. (Somnetics International, Inc.)
      • 6.5.12.1. Overview
      • 6.5.12.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.12.3. Product benchmarking
      • 6.5.12.4. Strategic initiatives
    • 6.5.13. Trudell Medical (Vyaire)
      • 6.5.13.1. Overview
      • 6.5.13.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.13.3. Product benchmarking
      • 6.5.13.4. Strategic initiatives
    • 6.5.14. Medical Depot, Inc. dba Drive DeVilbiss Healthcare.
      • 6.5.14.1. Overview
      • 6.5.14.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.14.3. Product benchmarking
      • 6.5.14.4. Strategic initiatives
    • 6.5.15. Invacare Corporation
      • 6.5.15.1. Overview
      • 6.5.15.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.15.3. Product benchmarking
      • 6.5.15.4. Strategic initiatives
    • 6.5.16. Others
      • 6.5.16.1. Overview
      • 6.5.16.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2024)
      • 6.5.16.3. Product benchmarking
      • 6.5.16.4. Strategic initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦